Categories
Health

Here Are All the COVID-19 Vaccines Currently in Clinical Testing – Motley Fool

https://www.fool.com/investing/2020/07/19/here-are-all-the-covid-19-vaccines-currently-in-cl.aspx

In phase 1/2 research study.

Sinopharm/ Beijing Institute of Biological Products.
Suspended SARS-CoV-2 vaccine.

Information sources: WHO, ClinicalTrials.gov, business press releases.
Modernas COVID-19 vaccine program has actually received the most promotion in the U.S. The biotech just recently announced the publication of results from a stage 1 research study of mRNA-1273 in The New England Journal of Medicine. Those results showed that Modernas COVID-19 vaccine candidate produced reducing the effects of antibodies (which can avoid viral infection) in all 45 individuals in the research study..
Its not unexpected that Moderna ranks as a big winner amongst biotech stocks in 2020. Far this year, Modernas shares are up well over 300%.
Chinese drugmaker Sinovac reported in June that its COVID-19 vaccine prospect CoronaVac produced neutralizing antibodies in over 90% of patients in a phase 1/2 scientific study. Arise from a phase 1 research study of AZD1222, the COVID-19 vaccine prospect being developed by AstraZeneca and the University of Oxford, are anticipated to be published on July 20 in The Lancet medical journal.
Its still prematurely to understand whether any of these vaccine candidates will be successful in late-stage screening. 74% of experimental vaccines that made it to phase 3 medical trials in between 2006 and 2015 went on to win FDA approval, according to BIO.

In phase 1/2 study.

Bharat Biotech.
Whole-virioninactivated vaccine.

In stage 3 testing (or soon will be).
There are three leaders in the COVID-19 vaccine race based on the clinical progression of their respective candidates. Each of these business COVID-19 vaccine candidates is either in stage 3 medical research studies or soon will be.

Cansino Biologics/ Beijing Institute of Biotechnology.
Ad5-nCoV.
In phase 2 study.

Walvax Biotechnology/ Peoples Liberation Army Academy of Military Sciences.
ARCoV.

Cadila Healthcare.
ZyCoV-D.

Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences.
Adjuvantedrecombinantprotein.
In stage 2 research study.

Status.

AnGes/ Takara Bio/ Osaka University.
DNA vaccine.
In phase 1/2 study.

What are the possibilities of FDA approval for a vaccine candidate in phase 1 screening? Modernas COVID-19 vaccine program has actually received the most publicity in the U.S.

Clover Pharmaceuticals/ GlaxoSmithKline / Dynavax.
SCB-2019.

Image source: Getty Images.

Organization( s).

In stage 1/2 research study.

NVX‑CoV2373.

Sinopharm/ Wuhan Institute of Biological Products.
Inactivated SARS-CoV-2 vaccine.

Company( s).

In stage 1/2 research study.

In stage 1 testing.
The field of early stage COVID-19 vaccine candidates is crowded. Of the 23 COVID-19 vaccine prospects presently in scientific screening, 18 remain in stage 1 research studies:.

Medicago / GlaxoSmithKline/ Dynavax.
Plant-derived virus-like particle.

Vaxine Pty Ltd/ Medy-Tox.

Status.

In phase 1/2 study.

When will a COVID-19 vaccine be available? How effective will it be? Those are two of the most important concerns being asked by many with the number of COVID-19 cases increasing in much of the U.S..
Unfortunately, the questions cant be responded to yet with a high level of self-confidence. But there are 23 COVID-19 vaccine prospects currently in scientific testing, according to the World Health Organization (WHO). When a COVID-19 vaccine might be readily available, the progress of these prospects can at least supply a hint as to. Here are those vaccine prospects and how most likely they might be to win regulatory approval.

In stage 1/2 study.

In stage 1/2 study.

In phase 1/2 study.

Imperial College London.
RNA vaccine.

Information sources: WHO, ClinicalTrials.gov, Chinese Clinical Trial Registry, business news release.
The Chinese armed force is already utilizing Cansinos speculative Ad5-nCoV vaccine under an one-year unique approval approved by Chinas Central Military Commission. The vaccine prospect isnt approved for usage outside of military workers at this time, however.
Neither of these 2 COVID-19 vaccine candidates is being tested in the U.S. at this point. The odds a speculative vaccine in a phase 2 scientific trial will eventually win FDA approval is low, based upon BIOs historic information– less than 25%.

Status.

Inovio Pharmaceuticals.
INO-4800.

In phase 1/2 research study.

Moderna (NASDAQ: MRNA) asdf.
mRNA-1273.
Stage 3 study scheduled to begin on July 27, 2020.

Novavax (NASDAQ: NVAX).

Genexine Consortium.
GX-19.

CSL / Sequirus/ University of Queensland.
Molecular clampstabilized spikeprotein withMF59 adjuvant.

Sinovac Biotech.
CoronaVac.
Stage 3 research study set up to start in July 2020.

In stage 1/2 research study.

In phase 1/2 research study.

Company( s).

Vaccine Candidate.

COVAX-19.

BioNTech (NASDAQ: BNTX)/ Pfizer (NYSE: PFE).

In stage 1/2 research study.

In phase 1/2 study.

CureVac.
CVnCoV.

Gamaleya Research Institute.
Gam-COVID-Vac.

Institute of Medical Biology/ Chinese Academy ofMedical Sciences.
Inactivated SARS-CoV-2 vaccine.

AstraZeneca (NYSE: AZN)/ University of Oxford.
AZD1222.
In stage 2/3 study.

In phase 1/2 study.

There are 23 COVID-19 vaccine prospects currently in clinical screening, according to the World Health Organization (WHO). The progress of these candidates can at least provide an idea as to when a COVID-19 vaccine may be offered. Here are those vaccine prospects and how likely they might be to win regulatory approval.

Information sources: WHO, ClinicalTrials.gov, business news release.
BioNTech and Pfizer reported favorable outcomes on July 1 for BNT162b1, one of four candidates in development. The FDA just recently approved Fast Track designation to two of those candidates, which leads the way for an expedited review procedure.
Novavax has drawn in a lot of attention for its COVID-19 vaccine prospect. Operation Warp Speed, the U.S. federal governments program to accelerate COVID-19 vaccine development, chosen NVX-CoV2373 to get $1.6 billion in funding.
What are the chances of FDA approval for a vaccine candidate in phase 1 testing? Very low, at least based upon historic data. Only 16% of speculative vaccines in early phase studies in between 2006 and 2015 ultimately won FDA approval, based on an analysis performed by biopharmaceutical industry trade organization BIO..
In stage 2 testing.
Two Chinese drugmakers are currently examining COVID-19 vaccine prospects in phase 2 medical research studies:.

BNT162.
( Four prospects).

Vaccine Candidate.

Vaccine Candidate.

In stage 1/2 research study.

In phase 1/2 study.

In stage 1/2 study.